M-Life

06/25/2023

M-Life is dedicated to developing new drugs for the treatment of the most difficult cancers. Here’s how we’re doing:

06/06/2022

M-Life is now working with Fallingst Technologies.

06/01/2022

M-Life is moving forward with an undisclosed investment firm for debt financing into M-Life's wholly owned subsidiary, M-Tubulin. The prospective deal is estimated at $25M with anticipated closing in 5 months.

www.m-lifesciences.com

The Future of Life Sciences Despite incredible technological advancements, the world is still struggling to cure diseases effectively and without harsh side effects. We are combining AI (artificial intelligence), advanced pattern recognition, molecular transcription, data fusion and solution space t...

05/03/2022

Recently we updated our website. Come see what's new at.

The Future of Life Sciences Despite incredible technological advancements, the world is still struggling to cure diseases effectively and without harsh side effects. We are combining AI (artificial intelligence), advanced pattern recognition, molecular transcription, data fusion and solution space t...

03/17/2022

https://www.biospace.com/article/m-life-multitargeting-cancer-drug-prospect-mls-222qld-successfully-advancing-through-pre-clinical-testing-/

M-Life’s™ Molecular Systems Approach is Proving Itself as the Next Generation for Drug Discovery.

02/11/2022

02/03/2022

Question: How can you be sure that P2L™ and MiST™ will produce molecules consistent with ‘real life’ performance?

Answer: Molecules have been synthesized and corroborate М-Lіfе™ platforms’ predictions. Individually, P2L™ model predictions for heart, liver and other significant toxicities have been validated via accurate toxic evaluation of historical drug failures. A variety of drugs pulled from market have been evaluated by the М-Lіfе™ platforms to assess their ability to identify toxicity, the type of toxicity and relative scale of toxicity. In all of these tests, the platforms correctly identified the scale and type of probable toxicity as well as the molecular features responsible for the toxicity.

02/01/2022

The current M-Life™ Intellectual Property portfolio includes:
⚕️M-Life™ Design Process IP
⚕️M-Life™, P2L™ and MiST™ Trademarks
⚕️Design Process and P2L/MiST™ platform Trade Secrets
⚕️Proprietary Data Repositories
⚕️Proprietary Software Related to P2L™ and MiST™ platforms

01/29/2022

Meet Our Team-
Our executive leadership team has extensive experience in clinical pharmacology and are working to reduce toxicity in chemotherapy treatment. Our hands-on expertise ensures quality scientific data and results in our ongoing development activities. Our hand picked team members have cross-functional experience and have worked on other biomed projects.

01/26/2022

The Team is composed of innovators and pioneers in the underlaying fields of M-Life’s™ technology. These fields include chemistry, chem-bioinformatics, biology, translational medicine, advanced mathematics, computer science, engineering, and physics. The Team holds patents and/or published seminal works on pattern recognition, molecule design, molecular synthesis, artificial intelligence, machine learning, advanced data structures, bio-informatics, toxicology, biology, target & phenotypical based discovery, proteomics, genomics as applied the development of new drugs, diagnostics, pathogen detection, molecular discovery, telecommunications, image processing and other technologies.

01/22/2022

Algorithms (like our P2L™ ) working from large chemical databases can predict a new chemical’s toxicity better than standard animal tests, suggests a study from Johns Hopkins Bloomberg School of Public Health.
We are very proud of the scorecard for our molecules.

01/18/2022

Meet Dr. Venu Madhav, Senior Scientist, is a seasoned Medicinal Chemist with over 12 years, 7 issued patents and 47 peer reviewed publications. Throughout his career he has worked in a commercial capacity for a Contract Research Organization (CRO), Senior Scientist for an early stage drug discovery company as well as in academic drug development research. Having led medicinal chemistry development efforts in a variety of areas, including the development of anti-cancer drugs, he has proven program management, drug design, molecular synthesis and testing skills. He also serves as a research scientist at the University of Arkansas for Medical Sciences in the College of Pharmacy, teaching research.